Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in chronic heart failure with reduced ejection fraction (HFrEF)
CTR20170308Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co.. Started Aug 2017; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20170308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170308.